US · biotech · cell therapy · parkinson's disease
One round we have observed, with the investors the report named. Every figure below came from a named source, and where the company reported the raise to the SEC itself, that is shown beside it.
Series C · Nov 2025 · $115M
ARCH Venture Partners lead, OrbiMed lead, Frazier Life Sciences lead, Revelation Partners lead, Cormorant Asset Management, Balyasny Asset Management, Kite (a Gilead Company), Prebys Ventures
Reported by Ventureburn
Missing a round, or an investor who was in one? Tell us.